<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108274</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-010</org_study_id>
    <secondary_id>U1111-1193-2774</secondary_id>
    <nct_id>NCT03108274</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants</brief_title>
  <official_title>A Three-Part Phase 1 Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the potential drug interaction between danicopan&#xD;
      (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part&#xD;
      study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1, Part 2, and Part 3 could be conducted concurrently or separately, and the order of the parts could be determined according to the needs of the program.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Observed Non-zero Concentration (AUC0-t) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Midazolam Maximum Observed Plasma Concentration (Cmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Midazolam Time To Reach Maximum Observed Plasma Concentration (Tmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Fexofenadine AUC0-t Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Fexofenadine AUC0-inf Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Fexofenadine Cmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Fexofenadine Tmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Mycophenolic Acid (MPA) and Mycophenolic Acid Glucuronide (MPAG) AUC0-t Following Single-dose Mycophenolate Mofetil (MMF) Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: MPA and MPAG AUC0-inf Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: MPA and MPAG Cmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: MPA and MPAG Tmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1-3: Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>7 (±1) days following the last dose in Period 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Danicopan and Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of midazolam.&#xD;
Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.&#xD;
Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Danicopan and Fexofenadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of fexofenadine.&#xD;
Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.&#xD;
Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Danicopan and MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single dose of MMF.&#xD;
Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.&#xD;
Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 1: Danicopan and Midazolam</arm_group_label>
    <arm_group_label>Part 2: Danicopan and Fexofenadine</arm_group_label>
    <arm_group_label>Part 3: Danicopan and MMF</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Oral syrup.</description>
    <arm_group_label>Part 1: Danicopan and Midazolam</arm_group_label>
    <other_name>Midazolam HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 2: Danicopan and Fexofenadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part 3: Danicopan and MMF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy was defined as having no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, physical examination, blood pressure and heart rate&#xD;
             measurements, 12-lead electrocardiogram, and clinical laboratory tests.&#xD;
&#xD;
          -  Body mass index of 18.5 to 32 kilograms (kg)/square meter with a minimum body weight&#xD;
             of 50 kg.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Mentally or legally incapacitated or significant emotional problems.&#xD;
&#xD;
          -  Any condition that might interfere with drug absorption.&#xD;
&#xD;
          -  History of sensitivity to study medication or other drug allergies.&#xD;
&#xD;
          -  Body temperature greater than or equal to 38°Celsius on Day -1 or Day 1 predose;&#xD;
             history of febrile illness within 14 days of the first dose.&#xD;
&#xD;
          -  Positive urine drug test; current tobacco/nicotine users and smokers; consumption of&#xD;
             alcohol within 72 hours of study drug administration.&#xD;
&#xD;
          -  Participated in another clinical study within 28 days prior to the first dose.&#xD;
&#xD;
          -  Significant laboratory abnormalities.&#xD;
&#xD;
          -  Blood donation of more than 500 milliliters within 3 months of the first dose;&#xD;
             received a blood transfusion or blood products within 6 months to the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Fexofenadine</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>Drug Interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

